CHRONIC PLAQUE PSORIASIS

This phase 3 study tested the drug bimekizumab in 133 Chinese adults with moderate to severe plaque psoriasis. Participants received either bimekizumab or a placebo for 16 weeks. The main goals were to see if bimekizumab could clear at least 90% of psoriasis (PASI90) and achieve …

This study tested a new drug called bimekizumab in 567 adults with moderate to severe plaque psoriasis. Participants received either bimekizumab, a placebo, or another active drug. The main goal was to see how well bimekizumab cleared skin lesions after 16 weeks. Results showed s…

This phase 3 study tested bimekizumab, a drug given by injection, against a placebo in 435 adults with moderate to severe plaque psoriasis. The main goal was to see how many people achieved at least 90% skin clearing after 16 weeks. The trial also looked at complete clearing and …

This Phase 3 trial tested bimekizumab against secukinumab and placebo in 743 adults with moderate to severe plaque psoriasis. The main goal was to see how many patients achieved complete skin clearance (PASI100) at 16 weeks. Bimekizumab showed superior results compared to secukin…

This study tested a new medicine called bimekizumab against an existing drug (adalimumab) in 478 adults with moderate to severe plaque psoriasis. The goal was to see if bimekizumab could clear more skin at 16 weeks. Participants received either bimekizumab or adalimumab, and then…

This study looked at the long-term safety and tolerability of bimekizumab in over 1,300 adults with moderate to severe plaque psoriasis. Participants who completed earlier studies received bimekizumab injections over several years. The main goal was to track side effects and see …

This Phase 2 trial tested the drug bimekizumab in 49 adults with moderate to severe plaque psoriasis. Participants received either bimekizumab or a placebo, and researchers measured how well the drug cleared skin and how long it stayed in the body. The goal was to see if bimekizu…

This completed study followed 2759 adults with moderate to severe plaque psoriasis to see how well risankizumab works compared to other commonly used biologic drugs. Researchers measured skin clearance and how long patients stayed on treatment. The goal was to understand real-wor…

This Phase 3 study tested the drug tildrakizumab in 99 adults with moderate to severe nail psoriasis. Participants received either the drug or a placebo for 28 weeks to see if it improved nail appearance and reduced pain. The trial is complete, and results may help determine if t…

This study looked at how the drug adalimumab affects gene activity in the skin of people with chronic plaque psoriasis. Researchers compared skin samples from normal, non-lesional, and lesional areas before and after treatment. The goal was to understand the immune changes that h…